Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

managed access agreement

- PMLiVE

NICE knocks back J&J’s depression nasal spray Spravato

Cites clinical and pricing uncertainty as basis of rejection

- PMLiVE

NICE leaves the ‘the NHS door’ open despite rejecting Bayer’s Vitrakvi

Initial guidance says drug is too costly but encourages further data

- PMLiVE

NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata

Cost-effectiveness watchdog issues a round of draft and final guidance

- PMLiVE

NICE rejects Akcea’s rare inherited disorder drug Waylivra

Draft guidance deems drug too costly for NHS use

- PMLiVE

NICE knocks back Roche’s Tecentriq for small cell lung cancer

Insufficient evidence to approve use in SCLC on the NHS

- PMLiVE

Pfizer’s Ibrance scores second-line breast cancer approval via NICE’s Cancer Drugs Fund

Around 3,200 women in England could be eligible for treatment

- PMLiVE

Thousands of EU staffers have left NHS since 2016, says Lib Dems

Figures come from information provided by 50 NHS hospital trusts

- PMLiVE

The NHS is facing shortages of lifesaving treatments, says internal document

Identifies 17 new shortages including drugs for cancer treatment

- PMLiVE

Election 2019: Labour tops Tory pledge on NHS spending

Pledge comes as campaigning for upcoming election gathers steam

Roche Basel Switzerland

Roche’s Spinraza, Zolgensma rival risdiplam hits the mark in SMA

Will file for approval in US and other world markets before end of the year

- PMLiVE

NICE backs first cannabis-based drugs, both from GW Pharma

Approved to treat patients with epilepsy and multiple sclerosis

- PMLiVE

NICE International relaunches, will offer advisory services

Meets growing demand from global health and social care organisations

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links